Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2011-01-25
2011-01-25
Bunner, Bridget E (Department: 1646)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C435S069100, C435S320100, C435S325000
Reexamination Certificate
active
07875710
ABSTRACT:
This disclosure provides tyrosine kinase protein and nucleic acid variants, particularly PDGFRA variants, which are activating forms of these molecules and are linked to neoplasms and/or the development or progression of cancer. The disclosure further provides methods of diagnosis and prognosis, and development of new therapeutic agents using these molecules and fragments thereof, and kits for employing these methods and compositions.
REFERENCES:
patent: 5686572 (1997-11-01), Wolf et al.
patent: 5795975 (1998-08-01), Wallach et al.
patent: 5795976 (1998-08-01), Oefner et al.
patent: 5833986 (1998-11-01), LaRochelle et al.
patent: 6187536 (2001-02-01), Weinberg et al.
patent: 6194158 (2001-02-01), Kroes et al.
patent: 6291661 (2001-09-01), Graddis et al.
patent: 7195876 (2007-03-01), Briesewitz et al.
Wells (1990) Biochemistry 29(37): 8509-8517.
Ngo et al (1994) “The Protein Folding Problem and Tertiary Structure Prediction, Chapter 14: Computational Complexity Protein Structure Prediction, and the Levinthal Paradox” pp. 433-440 and 492-495 only.
Bork (2000) Genome Research 10:398.
Skolnick et al (2000) Trends in Biotech. 18(1): 34.
Doerks et al (1998) Trends in Genetics 14(6): 248.
Brenner (1999) Trends in Genetics 15(4): 132.
Wang et al. (Nuc. Acids Res. 27: 4609-4618, 1999; p. 4617).
Kaufman et al (1999) Blood 94: 3178-3184.
Phillips, A., J Pharm Pharmacology 53: 1169-1174, 2001.
“Gleevec™ Shows Promise for Type of Gastrointestinal Tumor,”National Cancer Institute—Clinical Trial Resultshttp://www.cancer.gove/clinicaltrials/results/gleevec-shows-promise0202, posted Jul. 20, 2001; printed Feb. 26, 2005.
Abu-Duhier et al., “FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group,”J. Haematol, 111(1):190, 2000.
Abu-Duhier et al., “Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia,”J. Haematol, 113(4):983-988, 2001.
Al-Ali et al., “High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib,”Haematol J. 5(1):55-60, 2004.
Bai et al., “The SH2-containing Adapter Protein GRB10 interacts with BCR-ABL”Oncogene, 17:941-948, 1998.
Baxter et al., “The t(4:22)(q12;q11) in Atypical Chronic Myeloid Leukaemia fuses BCR to PDGFRA”Human Molecular Genetics, 11(12):1391-1397, 2002.
Blanke et al., “Evaluation of the Safety and Efficacy of an Oral Molecularly-Targeted Therapy, STI571, in Patients (Pts) with Unresectable or Metastatic Gastrointestinal Stromal Tumors (GISTS) Expressing C-KIT (CD117),”ASCO, May 12-15, 2001 (Meeting Abstract).
Borg et al., “Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects,”J. Clinical. Investigation, 114(3):379-388, 2004.
Chen et al., “Imatinib inhibits various types of activating mutant kit found in gastrointestinal stromal tumors,”J. Cancer, 105(1):130-135, 2003.
Corless et al., “Biology of gastrointestinal stromal tumors,”J. Clin. Oncol., 22(18):3813-3825, 2004.
Debiec-Rychter et al., “Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered in phase I and II stidies of the EORTC Soft Tissue and Bone Sarcoma Group,”Eur J Cancer, 40(5):689-95, 2004.
Demetri, “Targetingc-kitMutations in Solid Tumors: Scientific Rationale and Novel Therapeutic Options,”Semin Oncol., 5 Suppl 17:19-26, 2001.
Demetri et al., “Phase III dose-randomized study of imatinib mesylate (Gleevec, STI571) for GIST: intergroup S0033 early results,”ASCO, May 18-21, 2002 (Meeting Abstract).
Duensing et al., “Protein Kinase C theta (PKCtheta) expression and constitutive activation in gastrointestinal stromal tumors (GISTs),”Cancer Res., 64(15):5127-5131, 2004.
Fenski et al., “Constitutive activation of FLT3 in acute myeloid leukaemia and its consequences for growth of 32D cells,”J. Haematol, 108(2):322-330, 2000.
Gari et al., “c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia,”J. Haematol, 105(4):894-900, 1999.
Griswold et al., “Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis,”Blood, 104(9):2912-2918, 2004.
Heinrich et al., “Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor,”Blood, 96(3):925-932, 2000.
Heinrich et al., “Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alternations,”Hum. Pathol., 33(5):484-95, 2002.
Heinrich et al., “Inhibition of KIT Tyrosine Kinase Activity: A Novel Molecular Approach to the Treatment of KIT-Positive Malignancies,”J. Clinical Oncology, 20(6):1692-1703, 2002.
Heinrich et al., “KIT mutational status predicts clinical response to STI571 in patients with metastatic gastrointestinal stromal tumors (GISTs),”ASCO, May 18-21, 2002 (Meeting Abstract).
Heinrich et al., “Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor,”J. Clin Oncol., 21(23):4342-4349, 2003.
Heinrich et al., “PDGFRAActivating Mutations in Gastrointestinal Stromal Tumors,”Science. 299:708-710, 2003.
Heinrich et al., “Targeting mutant kinases in gastrointestinal stromal tumors: a paradigm for molecular therapy of other sarcomas,”Cancer Treatment Res,. 120:129-150, 2004.
Hirota et al., “Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours,”J Pathol. 193(4):505-510, 2001.
Hirota et al., “Gain-of-Function Mutations of Platelet-Derived Growth Factor Receptor α Gene in Gastrointestinal Stromal Tumors,”Gastroenterology, 125:660-667, 2003.
Hochhaus et al., “Interim analysis of imatinib treatment in 300 patients with chronic myelogenous leukemia (CML): evaluation of response and resistance,”ASCO, May 18-21, 2002 (Meeting Abstract).
Homo sapiensplatelet-derived growth factor receptor, alpha polypeptide (PDGFRA), mRNA, Locus ID: XM—011186, PRI Feb. 7, 2002,NCBI, printed Apr. 18, 2002.
Human DNA for alpha-platelet-derived growth factor receptor, exon 1, Locus ID: D50001S01, PRI Apr. 14, 2000,NCBI, printed Jun. 5, 2002.
Joensuu et al., “Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor,”N Engl J Med, 344(14):1052-1056, 2001.
Joensuu et al., “Gastrointestinal stromal tumor (GIST) patients who respond to imatinib (STI571, Gleevec) show marked decline of circulating levels of VEGF, KIT, and bFGF in serum, but not stem cell factor (SCF) levels,”ASCO, May 18-21, 2002 (Meeting Abstract).
Johnson et al., “Phase II study of STI571 (Gleevec™) for patients with small cell lung cancer,”ASCO, May 18-21, 2002 (Meeting Abstract).
Kubota et al., “Chemosensitivity of gastric cancer detected by cDNA microarray,”ASCO, May 18-21, 2002 (Meeting Abstract).
Madani et al., “Expression of KIT and epidermal growth factor receptor (EGFR) in chemotherapy refractory non-seminomatous germ cell tumors (GCT),”ASCO, May 28-21, 2002 (Meeting Abstract).
Medeiros et al., “KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications,”Am J. Surg Pathol,. 28(7):889-894, 2004.
Nakamura et al., “Abnormalities of the p53, N-ras, DCC and FLT-3 genes in myelodysplastic syndromes,”J. Nippon Med Sch, 68(2):143-148 (Apr. 2001) (English Abstract Only).
O'Farrell et al., “Analysis of mechanism of action and biomarkers for kinase inhibitor SU5416 in AML patients,”ASCO, May 18-21, 2002 (Meeting Abstract).
O'Farrell et al., “SU11248 is a novel FLT3
Corless Christopher C.
Demetri George D.
Fletcher Jonathan A.
Heinrich Michael C.
Brigham and Women's Hospital
Bunner Bridget E
Dana-Faber Cancer Institute
Howard Zachary C
Klarquist & Sparkman, LLP
LandOfFree
Nucleic acids encoding platelet derived growth factor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nucleic acids encoding platelet derived growth factor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleic acids encoding platelet derived growth factor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2727013